108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
康柏西普辅助治疗对糖尿病视网膜病变及视网膜静脉阻塞所致黄斑水肿患者激光治疗后症状改善的影响
Authors Cai L , Wang J, Huang D, Cai Z
Received 23 May 2025
Accepted for publication 5 September 2025
Published 6 October 2025 Volume 2025:18 Pages 6063—6071
DOI https://doi.org/10.2147/IJGM.S542427
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Brian C. Gilger
Lei Cai,1 Jingfeng Wang,2 Dongdong Huang,2 Zhang Cai2
1Department of Ophthalmology, The First Hospital of Putian, Putian, Fujian, 351100, People’s Republic of China; 2Department of Otorhinolaryngology, The First Hospital of Putian, Putian, Fujian, 351100, People’s Republic of China
Correspondence: Zhang Cai, Email c8n1em@163.com
Objective: To evaluate the effect of adjuvant Conbercept in patients with macular edema caused by diabetic retinopathy (DR) or retinal vein occlusion (RVO) undergoing laser therapy, and its impact on symptom improvement.
Methods: This retrospective cohort study analyzed 63 patients treated between January 2022 and January 2025. Patients were assigned to a control group (n=31, laser alone) or an observation group (n=32, laser plus Conbercept). Outcomes included clinical efficacy, symptom improvement time (fundus hemorrhage absorption, exudate absorption, macular edema resolution), best corrected visual acuity (BCVA), retinal thickness (central fovea, superior, nasal, inferior, temporal), and adverse events.
Results: The total effective rate was higher in the observation group (96.88%) than in the control group (74.19%) (P< 0.05). Symptom improvement times were shorter in the observation group: fundus hemorrhage absorption (2.32± 0.25 vs 3.23± 0.37 weeks), exudate absorption (10.23± 1.38 vs 12.19± 1.46 weeks), and macular edema resolution (4.31± 0.32 vs 5.69± 0.43 weeks) (all P< 0.05). BCVA improved significantly in both groups at 1 and 3 months, with greater improvement in the observation group (P< 0.05). Retinal thickness decreased in all measured regions in both groups, with more pronounced reductions in the observation group (P< 0.05). Adverse event rates did not differ significantly (9.38% vs 12.90%, P> 0.05).
Conclusion: Conbercept adjunctive to laser therapy in DR- or RVO-related macular edema enhances clinical efficacy, accelerates symptom resolution, improves visual and retinal function, and does not increase adverse reaction risk.
Keywords: diabetic retinopathy, retinal vein occlusion, macular edema, laser, conbercept
1Department of Ophthalmology, The First Hospital of Putian, Putian, Fujian, 351100, People’s Republic of China; 2Department of Otorhinolaryngology, The First Hospital of Putian, Putian, Fujian, 351100, People’s Republic of China
Correspondence: Zhang Cai, Email c8n1em@163.com
Objective: To evaluate the effect of adjuvant Conbercept in patients with macular edema caused by diabetic retinopathy (DR) or retinal vein occlusion (RVO) undergoing laser therapy, and its impact on symptom improvement.
Methods: This retrospective cohort study analyzed 63 patients treated between January 2022 and January 2025. Patients were assigned to a control group (n=31, laser alone) or an observation group (n=32, laser plus Conbercept). Outcomes included clinical efficacy, symptom improvement time (fundus hemorrhage absorption, exudate absorption, macular edema resolution), best corrected visual acuity (BCVA), retinal thickness (central fovea, superior, nasal, inferior, temporal), and adverse events.
Results: The total effective rate was higher in the observation group (96.88%) than in the control group (74.19%) (P< 0.05). Symptom improvement times were shorter in the observation group: fundus hemorrhage absorption (2.32± 0.25 vs 3.23± 0.37 weeks), exudate absorption (10.23± 1.38 vs 12.19± 1.46 weeks), and macular edema resolution (4.31± 0.32 vs 5.69± 0.43 weeks) (all P< 0.05). BCVA improved significantly in both groups at 1 and 3 months, with greater improvement in the observation group (P< 0.05). Retinal thickness decreased in all measured regions in both groups, with more pronounced reductions in the observation group (P< 0.05). Adverse event rates did not differ significantly (9.38% vs 12.90%, P> 0.05).
Conclusion: Conbercept adjunctive to laser therapy in DR- or RVO-related macular edema enhances clinical efficacy, accelerates symptom resolution, improves visual and retinal function, and does not increase adverse reaction risk.
Keywords: diabetic retinopathy, retinal vein occlusion, macular edema, laser, conbercept